A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2019
Price : $35 *
At a glance
- Drugs Linsitinib (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone; Erlotinib; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 24 Jan 2017 Status changed from active, no longer recruiting to completed.
- 05 Feb 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 26 Jan 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.